July 26th 2024
The molecule can be a potential treatment that counters effects of early-life antibiotics, which can impact the gut microbiota and increase the risk of childhood atopy and asthma.
Understanding the Impact of Allelic Gene Variants on Pediatric Pain Relief
January 9th 2024Studies have shown that higher expression of CYP2D6 alleles in adults results in excessive production of active metabolites, leading to either therapeutic failure, increased exposure, or more severe adverse effects.
Read More
High-Risk Pediatric Patients With Antiphospholipid Syndrome Present Risk of Severe Health Issues
December 11th 2023The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.
Read More
FDA Approves Isavuconazonium Sulfate to Treat Invasive Aspergillosis, Invasive Mucormycotic
December 8th 2023The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric patients with invasive aspergillosia and invasive mucormycotic who are as young as age 1.
Read More
CDC, FDA Announce 77,000 Additional Doses for Nirsevimab as Infant Treatment of RSV
November 22nd 2023Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.
Read More
CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More